ClinicalTrials.Veeva

Menu

A Study of MK-1084 Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: [14C]MK-1084

Study type

Interventional

Funder types

Industry

Identifiers

NCT06687759
1084-006
MK-1084-006 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to learn what happens to MK-1084 in a healthy person's body over time and how it is cleared from the body.

Enrollment

8 patients

Sex

Male

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Key inclusion criteria include but are not limited to the following:

  • Is in good health based on medical history, physical examination,vital signs measurements, and electrocardiogram (ECG)s performed before randomization.
  • Has a body mass index (BMI) 18 to 32 kg/m2, inclusive, at screening

Exclusion criteria

The key exclusion criteria include but are not limited to the following:

  • Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
  • Has a history of cancer.

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

8 participants in 1 patient group

Carbon-14 radiolabeled [14C] MK-1084
Experimental group
Description:
Participants receive single oral dose of MK-1084 on Day 1.
Treatment:
Drug: [14C]MK-1084

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems